The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash collections from financial royalty assets | 3,354,750 | 2,983,410 | 3,201,410 | 2,507,236 |
| Cash collections from intangible royalty assets | 720 | 14,647 | 1,302 | 72,943 |
| Other royalty cash collections | 114,021 | 108,846 | 158,843 | 69,891 |
| Distributions from equity method investees | 13,396 | 13,396 | 18,823 | 39,142 |
| Interest received | 34,308 | 46,482 | 71,604 | 24,982 |
| Derivative collateral received | - | - | 0 | 0 |
| Derivative collateral posted | - | - | 0 | 0 |
| Termination payments on derivative instruments | - | - | 0 | 0 |
| Development-stage funding payments - ongoing | - | 2,000 | 2,000 | 2,106 |
| Development-stage funding payments - upfront and milestone | - | 0 | 50,000 | 175,000 |
| Development-stage funding payments | 452,000 | - | - | - |
| Payments for operating and professional costs | 288,138 | 236,225 | 243,012 | 222,969 |
| Payments for employee epas | 10,943 | - | - | - |
| Interest paid | 276,291 | 159,570 | 169,168 | 170,139 |
| Net cash provided by operating activities | 2,489,823 | 2,768,986 | 2,987,802 | 2,143,980 |
| Acquisition of businesses, net of cash acquired | 74,416 | - | - | - |
| Distributions from equity method investees | 105,149 | 23,641 | 43,882 | 0 |
| Investments in equity method investees | 0 | 10,955 | 12,542 | 9,896 |
| Purchases of equity securities | 58,427 | 62,500 | 0 | 87,785 |
| Proceeds from equity securities | 34,723 | 98,575 | - | 211,158 |
| Purchases of available for sale debt securities | 175,000 | 150,000 | 0 | 479,559 |
| Proceeds from available for sale debt securities | 21,226 | 19,786 | 1,440 | 542,044 |
| Purchases of marketable securities | - | 0 | 0 | 234,869 |
| Proceeds from sales of available for sale debt securities | 510,553 | - | - | - |
| Proceeds from sales and maturities of marketable securities | 0 | 0 | 24,391 | 792,341 |
| Acquisitions of financial royalty assets | 1,697,729 | 2,505,701 | 2,115,522 | 1,741,640 |
| Acquisitions of other financial assets | 0 | 18,000 | 0 | 21,215 |
| Milestone payments | 271,313 | 75,000 | 12,400 | 0 |
| Other | 8,946 | -2,039 | 2,038 | - |
| Net cash used in investing activities | -1,614,180 | -2,678,115 | -2,072,789 | -1,029,421 |
| Distributions to shareholders/unitholders | - | - | - | 0 |
| Distributions to legacy non-controlling interests - portfolio receipts | - | 362,280 | 376,987 | 441,963 |
| Distributions to legacy non-controlling interests - other | - | 0 | 0 | 31,301 |
| Distributions to legacy non-controlling interests - portfolio receipts | 354,901 | - | - | - |
| Distributions to continuing non-controlling interests | 167,475 | 125,159 | 119,534 | 144,115 |
| Dividends to shareholders | 378,253 | 376,465 | 358,327 | 333,322 |
| Repurchases of class a ordinary shares | 1,227,383 | 229,651 | 304,759 | - |
| Contributions from legacy non-controlling interests - r&d | 220 | 747 | 543 | 1,059 |
| Contributions from non-controlling interests - other | 5,697 | 4,360 | 6,933 | 6,133 |
| Cash acquired in connection with purchase of non-controlling interest | 0 | 0 | 4,973 | - |
| Proceeds from revolving credit facility | 1,275,000 | 0 | 350,000 | - |
| Scheduled repayments of long-term debt | - | - | - | 0 |
| Repayment of revolving credit facility | 1,275,000 | - | 350,000 | - |
| Repayments of long-term debt | - | - | - | 0 |
| Repayment of long-term debt | 1,000,000 | 0 | 1,000,000 | - |
| Proceeds from issuance of long-term debt, net of discount | 1,954,475 | 1,471,235 | 0 | - |
| Debt issuance costs and other | 16,563 | 12,616 | 1,596 | 1,347 |
| Proceeds from issuance of class a ordinary shares upon ipo, net of offering costs | - | - | - | 0 |
| Other | -1,790 | -9,026 | - | - |
| Net cash (used in)/provided by financing activities | -1,185,973 | 361,145 | -2,148,754 | -944,856 |
| Net change in cash and cash equivalents | -310,330 | 452,016 | -1,233,741 | 169,703 |
| Cash and cash equivalents at beginning of period | 929,026 | 477,010 | 1,710,751 | 1,541,048 |
| Cash and cash equivalents at end of period | 618,696 | 929,026 | 477,010 | 1,710,751 |
Royalty Pharma plc (RPRX)
Royalty Pharma plc (RPRX)